Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed amning

Janusmed amning – BEKEMV

Janusmed amning tillhandahåller generella rekommendationer om huruvida ett friskt fullgånget spädbarn kan ammas när modern använder olika läkemedel. Observera att prematura och/eller sjuka spädbarn alltid kräver särskilda överväganden. Om du inte är medicinskt utbildad, läs först vår information för patienter och allmänhet.

För att komma till startsidan för Janusmed amning och för att göra sökningar klicka här.

Tillbaka till index
2 2
2 2

Ekulizumab Testmiljö

Ekulizumab

Klass : 2

Visa all info

Skriv ut

Kontakta oss

  1. Sharma R, Keyzner A, Liu J, Bradley T, Allen SL. Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis. Leuk Res Rep. 2015;4(1):36-8.

  2. Kelly RJ, Höchsmann B, Szer J, Kulasekararaj A, de Guibert S, Röth A et al. Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med. 2015;373(11):1032-9.

  3. Miyasaka N, Miura O, Kawaguchi T, Arima N, Morishita E, Usuki K et al. Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review. Int J Hematol. 2016;103(6):703-12.

  4. Sarris I, Gandhi S, Koumis A, et al. Pregnancy outcome and safety of breastfeeding in two patients with paroxysmal nocturnal haemoglobinuria (PNH) treated with eculizumab. Arch Dis Child Fetal Neonatal Ed 2012;97(Suppl. 1):Abstract PP.43 current.

  5. Frairia C, Aydin S, Audisio E, et al. Breakthrough hemolysis and thromboembolism controlled by eculizumab during pregnancy in paroxysmal noctural hemoglobinuria (PNH): A single institution experience. HemaSphere 2018;2 (Suppl 2):835-6.

  6. Vinogradova M, Kulagin A, Kirsanova T, et al. Pregnancy outcomes in paroxysmal nocturnal hemoglobinuria depending on the therapeutic approach. Abstracts of the 57th Annual Scientific Meeting of the British Society for Haematology, 27-29 March 2017, Brighton, UK. Br J Haematol. 2017 Mar;176 Suppl 1:5-145.

  7. Socié G, Caby-Tosi MP, Marantz JL, Cole A, Bedrosian CL, Gasteyger C et al. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. Br J Haematol. 2019;185(2):297-310.

  8. Aydin S, Audisio E, Iovino G, et al. Breakthrough hemolysis controlled by eculizumab escalation during pregnancy in paroxysmal noctural hemoglobinuria (PNH): A single case report. Haematologica. 2017;102 Suppl 3:58. Abstract.

  1. Sharma R, Keyzner A, Liu J, Bradley T, Allen SL. Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis. Leuk Res Rep. 2015;4(1):36-8.
  2. Kelly RJ, Höchsmann B, Szer J, Kulasekararaj A, de Guibert S, Röth A et al. Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria. N Engl J Med. 2015;373(11):1032-9.
  3. Miyasaka N, Miura O, Kawaguchi T, Arima N, Morishita E, Usuki K et al. Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review. Int J Hematol. 2016;103(6):703-12.
  4. Sarris I, Gandhi S, Koumis A, et al. Pregnancy outcome and safety of breastfeeding in two patients with paroxysmal nocturnal haemoglobinuria (PNH) treated with eculizumab. Arch Dis Child Fetal Neonatal Ed 2012;97(Suppl. 1):Abstract PP.43 current.
  5. Frairia C, Aydin S, Audisio E, et al. Breakthrough hemolysis and thromboembolism controlled by eculizumab during pregnancy in paroxysmal noctural hemoglobinuria (PNH): A single institution experience. HemaSphere 2018;2 (Suppl 2):835-6.
  6. Vinogradova M, Kulagin A, Kirsanova T, et al. Pregnancy outcomes in paroxysmal nocturnal hemoglobinuria depending on the therapeutic approach. Abstracts of the 57th Annual Scientific Meeting of the British Society for Haematology, 27-29 March 2017, Brighton, UK. Br J Haematol. 2017 Mar;176 Suppl 1:5-145.
  7. Socié G, Caby-Tosi MP, Marantz JL, Cole A, Bedrosian CL, Gasteyger C et al. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. Br J Haematol. 2019;185(2):297-310.
  8. Aydin S, Audisio E, Iovino G, et al. Breakthrough hemolysis controlled by eculizumab escalation during pregnancy in paroxysmal noctural hemoglobinuria (PNH): A single case report. Haematologica. 2017;102 Suppl 3:58. Abstract.

Innehållet senast uppdaterat 11/7/2024